NovaBridge Biosciences - Ordinary Shares, par value $0.0001 per share (Including Ordinary Shares Underlying American Depository Shares) (NBP) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2020 to Q4 2025

Type / Class
Equity / Ordinary Shares, par value $0.0001 per share (Including Ordinary Shares Underlying American Depository Shares)
Symbol
NBP on Nasdaq
Shares outstanding
265,214,861
Price per share
$3.87
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
33,180,935
Total reported value
$132,060,061
% of total 13F portfolios
0%
Share change
+3,640,993
Value change
+$14,565,334
Number of holders
57
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of NovaBridge Biosciences - Ordinary Shares, par value $0.0001 per share (Including Ordinary Shares Underlying American Depository Shares) (NBP) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Everest Medicines Ltd 16% $90,577,645 42,524,716 Everest Medicines Limited 05 Aug 2025
CBC Investment I-Mab Ltd 12% +11% $121,227,193 +$11,952,376 30,499,709 +11% Wei Fu 29 Jan 2026

As of 31 Dec 2025, 57 institutional investors reported holding 33,180,935 shares of NovaBridge Biosciences - Ordinary Shares, par value $0.0001 per share (Including Ordinary Shares Underlying American Depository Shares) (NBP). This represents 13% of the company’s total 265,214,861 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of NovaBridge Biosciences - Ordinary Shares, par value $0.0001 per share (Including Ordinary Shares Underlying American Depository Shares) (NBP) together control 12% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
JANUS HENDERSON GROUP PLC 3.2% 8,436,641 +5.6% 0.02% $33,577,831
HHLR ADVISORS, LTD. 2.3% 5,980,568 0% 0.77% $23,802,661
MORGAN STANLEY 1.4% 3,785,502 +70% 0% $15,066,298
Siren, L.L.C. 1.1% 3,000,000 +157% 0.36% $11,940,000
Point72 Asset Management, L.P. 0.87% 2,298,501 +2872% 0.01% $9,148,034
Ariose Capital Management Ltd 0.51% 1,363,515 -20% 1.8% $5,426,790
Candriam S.C.A. 0.43% 1,132,563 0% 0.02% $4,507,793
Woodline Partners LP 0.4% 1,050,000 0% 0.02% $4,179,000
ADAGE CAPITAL PARTNERS GP, L.L.C. 0.38% 1,000,000 -70% 0.01% $3,980,000
MILLENNIUM MANAGEMENT LLC 0.32% 846,008 +3668% 0% $3,367,112
BARCLAYS PLC 0.24% 628,923 +59% 0% $2,503,113
BlackRock, Inc. 0.23% 618,347 0% $2,461,021
Exome Asset Management LLC 0.19% 499,587 -65% 1% $1,988,356
AIHC Capital Management Ltd 0.16% 413,979 0% 1.5% $1,647,636
STATE STREET CORP 0.14% 359,878 +6.7% 0% $1,432,314
Connor, Clark & Lunn Investment Management Ltd. 0.07% 191,714 +17% 0% $763,022
UBS Group AG 0.07% 181,776 -38% 0% $723,468
DIMENSIONAL FUND ADVISORS LP 0.06% 148,452 +50% 0% $590,839
GOLDMAN SACHS GROUP INC 0.05% 140,946 -35% 0% $560,965
XTX Topco Ltd 0.05% 140,867 +95% 0.01% $560,651
JPMORGAN CHASE & CO 0.05% 131,830 -12% 0% $524,683
Taikang Asset Management (Hong Kong) Co Ltd 0.05% 128,765 0.05% $512,485
BNP PARIBAS FINANCIAL MARKETS 0.04% 116,705 0% 0% $464,486
ALPS ADVISORS INC 0.04% 112,451 +0.86% 0% $447,555
DYMON ASIA CAPITAL (SINGAPORE) PTE. LTD. 0.03% 80,400 0.07% $319,992

Institutional Holders of NovaBridge Biosciences - Ordinary Shares, par value $0.0001 per share (Including Ordinary Shares Underlying American Depository Shares) (NBP) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 33,180,935 $132,060,061 +$14,565,334 $3.98 57
2025 Q3 29,690,135 $112,309,052 +$77,501,715 $3.78 42
2025 Q2 9,395,986 $22,737,366 +$2,030,864 $2.42 32
2025 Q1 8,993,007 $7,408,233 -$2,236,666 $0.82 29
2024 Q4 11,912,678 $10,125,354 -$4,196,499 $0.85 27
2024 Q3 14,193,703 $17,600,522 -$1,644,775 $1.24 27
2024 Q2 15,140,525 $25,329,475 +$4,917,141 $1.67 37
2024 Q1 12,194,479 $22,682,620 -$591,267 $1.86 38
2023 Q4 12,343,395 $23,450,292 -$3,932,021 $1.90 43
2023 Q3 15,251,229 $20,128,696 -$8,412,218 $1.32 46
2023 Q2 18,691,045 $55,880,438 -$6,382,969 $2.99 46
2023 Q1 20,700,388 $71,623,449 -$16,502,335 $3.46 51
2022 Q4 24,863,205 $103,919,915 -$23,835,362 $4.18 63
2022 Q3 30,756,340 $123,319,030 -$78,451,098 $4.01 69
2022 Q2 38,195,150 $430,214,056 -$43,072,457 $11.30 91
2022 Q1 40,274,792 $654,272,172 -$2,809,989 $16.24 112
2021 Q4 39,063,350 $1,843,596,654 +$49,692,681 $47.39 127
2021 Q3 36,035,033 $2,613,664,389 +$445,184,584 $72.49 140
2021 Q2 28,287,880 $2,375,233,906 +$495,487,800 $83.95 133
2021 Q1 23,316,491 $1,130,077,433 +$490,958,954 $48.47 78
2020 Q4 13,056,509 $615,418,000 +$200,018,636 $47.15 63
2020 Q3 9,526,320 $447,661,000 +$236,962,427 $47.03 48
2020 Q2 3,298,968 $97,724,000 -$2,617,263 $29.93 19
2020 Q1 3,439,668 $44,717,000 +$44,717,000 $13.00 15